Drug Trial Radar · NCT05691244
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
514
Planned (sponsor's estimate)
Start
Jul 24, 2025
Primary completion
Sep 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.
Conditions
- Acute Ischemic Stroke
- Cerebral Stroke
Interventions
Drug: Normal SalineDrug
Normal saline to be used as vehicle in the phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
SovateltideDrug
Phase-III study to assess efficacy of sovateltide in patients with acute cerebral ischemic stroke.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the efficacy of sovateltide in patients with acute cerebral ischemic stroke assessed by modified Rankin Scale (mRS) score of 0-2 at day 90 post-randomization.Time frame: Day 1 through Day 90
Locations
57 sites in 5 countries. Site status is shown where the registry gives one.
The University of Arizona - College of Medicine
Tucson, Arizona · Recruiting
Mercy Medical Group
Carmichael, California · Recruiting
St. John's Regional Medical Center
Oxnard, California · Recruiting
Sarasota Memorial Hospital
Sarasota, Florida · Recruiting
Wellstar Kennestone Hospital
Marietta, Georgia · Recruiting
SSM Health Neurosciences
Bridgeton, Missouri · Recruiting
Hackensack University Medical Center at Paramus
Paramus, New Jersey · Recruiting
UNC Medical Center
Chapel Hill, North Carolina · Recruiting
Guilford Neurologic Associates Inc
Greensboro, North Carolina · Recruiting
OSU Wexner Medical Center
Columbus, Ohio · Recruiting
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania · Recruiting
CHI Memorial Neuroscience Institute
Chattanooga, Tennessee · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Houston Medical Neurological Institute
Houston, Texas · Recruiting
Memorial Hermann Hospital
Houston, Texas · Recruiting
Liverpool Hospital
Liverpool, New South Wales, Australia · Recruiting
RHON-KLINIKUM Campus Bad Neustadt
Bad Neustadt an der Saale, Germany · Recruiting
Universitaetsklinikum Erlangen
Erlangen, Germany · Recruiting
Universitätsklinikum Essen AöR
Essen, Germany · Recruiting
Universitätsklinikum Schleswig-Holstein AöR
Lübeck, Germany · Recruiting
University Hospital Tuebingen
Tübingen, Germany · Recruiting
Klinikum Altenburger Land GmbH
Altenburg, Altenburg, Germany · Recruiting
Universitaetsklinikum Goettingen
Göttingen, Lower Saxony, Germany · Recruiting
Klinikum der Stadt Ludwigshafen gGmbh
Rhein, Ludwigshafen Am, Germany · Recruiting
Muhlenkreiskliniken (MKK) - Johannes Wesling Klinikum Minden - Neurologische Klinik
Minden, North Rhine-Westphalia, Germany · Recruiting
Klinik fuer Neurologie, Stroke Unit und Fruehrehabilitation Dorstener Strae 151
Recklinghausen, Recklinghausen, Germany · Recruiting
Charite-Universitaetsmedizin Berlin
Berlin, State of Berlin, Germany · Recruiting
Instituto de Investigación Biomédica de A Coruña
A Coruña, Spain · Recruiting
Hospital Universitario Infanta Cristina (HUB)
Badajoz, Spain · Recruiting
Hospital Universitario de Cruces
Barakaldo, Spain · Recruiting
Institut Catala d'Oncologia (ICO) - Hospital Universitari Doctor Josep Trueta
Girona, Spain · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Hospital Clinico San Carlos
Madrid, Spain · Recruiting
Medical Imbrain S.L.
Melilla, Spain · Recruiting
Hospital Clinico Universitario de Santiago
Santiago, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain · Recruiting
Hospital Universitario Miguel Servet
Zaragoza, Spain · Recruiting
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.